Already launching in December with one of the largest series A rounds in history, Juno Therapeutics extends the venture round by a further $25m.

Juno Therapeutics, an oncology spin-out of three cancer research institutes, has extended its already sizable series A to $145m.

Amazon founder Jeff Bezos’ personal investment company Bezos Expeditions joined the round along with venture firm Venrock. The two join ARCH Venture Partners, a venture firm once part of the University of Chicago, and the Alaska Permanent Fund, a state-managed investment vehicle which draws on Alaskan oil money to create a post-oil nest egg for the state.

Seattle-based Juno is commercialising…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?